Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (2820)	9/17/1998 12:32:00 AM
From: Kevin Podsiadlik	Read Replies (1) \| Respond to of 4634

As I understand them: Pentalyte is essentially Hextend with pentastarch substituted for hetastarch. Given its similarity to Hextend, the fact that it's only in development stage right now seems to indicate that Biotime could only gather the money together to send one product through the FDA pipeline, and that funding for the development of its other products is strongly dependent on Hextend's success. (They'll also probably want to be hiring additions to their current staff of 13.) HetaCool and HetaFreeze embody what Biotime really wants to be when it grows up: a cryogenics company. HetaCool is based on the concept of performing certain critical surgeries at very low temperatures, during which HetaCool would replace the patient's blood entirely. HetaFreeze is for long-term organ storage. The company's site is at biotimeinc.com (in case you get tired of the inch.com site)